Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (139) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 21:28 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.1
- Combined market value
- SAR 18.98T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | SAR 254.9B | SAR 79.78 | 1.71% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | SAR 1.27T | SAR 516.81 | 3.90% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | SAR 22.4B | SAR 1,120.46 | 1.67% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.7 | SAR 37.5B | SAR 248.02 | 5.44% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.2 | SAR 184.8B | SAR 158.40 | 0.92% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.3 | SAR 59.7B | SAR 929.39 | 2.93% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | SAR 28B | SAR 356.53 | 0.06% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.7 | SAR 28.6B | SAR 82.07 | 3.60% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.7 | SAR 172.9B | SAR 1,513.90 | 2.34% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | SAR 27.8B | SAR 254.28 | 3.25% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.1 | SAR 1.9T | SAR 1,072.82 | 2.33% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 44.9 | SAR 148.1B | SAR 257.58 | 0.01% down | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 44.9 | SAR 4.62T | SAR 5,186.70 | 2.32% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.6 | SAR 117.9B | SAR 191.19 | 1.91% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | SAR 46.8B | SAR 56.19 | 1.28% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.4 | SAR 2.46T | SAR 1,022.90 | 2.15% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.1 | SAR 599.9B | SAR 105.25 | 1.44% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.0 | SAR 678.8B | SAR 391.90 | 0.22% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.5 | SAR 510.2B | SAR 2,012.22 | 0.42% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | SAR 1.1T | SAR 582.19 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | SAR 31.1B | SAR 476.98 | 2.00% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | SAR 1.04T | SAR 670.53 | 1.93% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.4 | SAR 424.4B | SAR 176.75 | 0.86% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.8 | SAR 92.2B | SAR 2,165.60 | 1.16% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | SAR 366.9B | SAR 3,546.68 | 1.28% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | SAR 66.5B | SAR 1,014.01 | 0.32% down | 28% up | ||
| 27 | GSKGSK · Health Care | 16.9 | SAR 365.3B | SAR 182.22 | 1.34% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.6 | SAR 130.4B | SAR 320.97 | 2.50% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.2 | SAR 456.7B | SAR 223.41 | 2.92% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | SAR 21.6B | SAR 31.77 | 1.85% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | SAR 651.9B | SAR 147.90 | 3.12% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | SAR 75.1B | SAR 560.40 | 4.54% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | SAR 17B | SAR 155.18 | 1.59% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (139) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 21:28 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of SAR 18.98T as of 18 Nov 2026, 21:28 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.